

Basal Cell Carcinoma

Non-Pigmented Skin Lesions

SKIN0059

Multicenter
 Randomized
 Double-Blind
 Vehicle-Controlled
 Phase III Efficacy
 & Safety Study of
 Patidegib Gel 2%
 for the Reduction
 of Disease Burden
 of Persistently
 Developing Basal
 Cell Carcinomas
 (BCCs) in
 Subjects with
 Gorlin Syndrome

PI: Sarin
 Sponsor: Sol-Gel
 Technologies Ltd.

Priority #1

SKIN0035

[Identification of
 Genetic Mutations
 in High Risk
 Patients with
 Non-Melanoma
 Skin Cancer](#)

PI: Sarin
 Sponsor: Stanford
 University

Priority #2

MEL0014

[Change Detection
 of Cutaneous
 Lesions using
 Image Capture
 and Machine
 Learning](#)

PI: Novoa
 Sponsor: Stanford
 University

Priority #3




BCC



See BCC
 Flowchart



SCC

See SCC
 Flowchart

KEY

-  Pending
-  Open for Enrollment
-  Observational Study

-  Optional Path
- [Link](#) Trial Posting
-  Enrollment on Hold

-  Extension Study
-  Immunotherapy